Propofol Triggers Cell Death in Lung Cancer Cells by Increasing PANX1 Expression, Activating the Mitochondrial Cell...

Area of Science:

• Oncology
• Cell Biology
• Pharmacology

Background:

• Lung cancer poses a significant global health challenge due to treatment resistance.
• Propofol, an anesthetic, exhibits potential anti-cancer properties.
• Understanding propofol's mechanism in lung cancer is crucial for developing novel therapies.

Purpose of the Study:

• To investigate propofol's effects on lung cancer cell death.
• To elucidate the roles of Pannexin 1 (PANX1) and reactive oxygen species (ROS) in propofol-induced apoptosis.
• To explore the activation of the mitochondrial cell death pathway by propofol.

Main Methods:

• Utilized A549 lung cancer cell line exposed to propofol, H2O2, and N-acetylcysteine (NAC).
• Assessed cell viability, proliferation, invasion, ROS levels, apoptosis, and mitochondrial membrane potential using various assays (EdU, colony formation, Transwell, DCFH-DA, TUNEL, JC-1).
• Quantified protein levels of PANX1, Bcl-2, Bax, caspase-3, and Cytochrome C via Western blot; investigated PANX1's role using siRNA.

Main Results:

• Propofol demonstrated dose-dependent inhibition of lung cancer cell growth, proliferation, and invasion, linked to increased ROS production.
• Propofol treatment significantly upregulated PANX1 expression and activated the mitochondrial apoptosis pathway, evidenced by increased mitochondrial membrane potential.
• PANX1 inhibition attenuated propofol-induced apoptosis, highlighting its critical role in the observed anti-cancer effects.

Conclusions:

• Propofol induces lung cancer cell death by upregulating PANX1, increasing ROS production, and activating the mitochondrial apoptosis pathway.
• Targeting PANX1 and modulating ROS levels represent potential strategies to enhance propofol's anti-cancer efficacy.
• These findings offer insights into novel therapeutic approaches for lung cancer treatment.